Table 2.
Median of bradykinin receptors 1 and 2 expression on lymphocytes and monocytes. Statistical significance of the results was analyzed with a Mann–Whitney test.
| Healthy Control Group (% of Cells) |
HAE Patients during Remission (% of Cells) |
HAE Patients during Attack (% of Cells) |
p-Value Attack vs. Control | |
|---|---|---|---|---|
|
BR1 level on CD3+ (min-max) |
3.6 (3.10–4.65) |
5.06 (4.09–5.97) |
8.19 (6.41–11.33) |
<0.0001 |
|
BR1 level on CD4+ (min-max) |
2.88 (2.30–4.25) |
3.55 (2.89–4.13) |
6.50 (5.14–9.35) |
<0.0001 |
|
BR1 level on CD8+ (min-max) |
5.90 (4.50–7.90) |
7.62 (6.05–9.83) |
11.56 (9.83–15.90) |
<0.0001 |
|
BR2 level on CD3+ (min-max) |
7.35 (4.22–17.33) |
9.70 (3.65–29.79) |
18.57 (7.66–36.58) |
0.016 |
|
BR2 level on CD4+ (min-max) |
7.47 (3.98–14.75) |
9.78 (4.59–23.59) |
18.98 (8.60–35.52) |
0.005 |
|
BR2 level on CD8+ (min-max) |
11.67 (4.27–19.83) |
15.90 (8.32–39.13) |
26.59 (12.49–54.13) |
0.0044 |
|
BR1 level on HLA-DR+CD14+ (min-max) |
26.19 (22.12–29.51) |
29.94 (24.73–32.54) |
37.65 (30.57–59.72) |
<0.0001 |
|
BR1 level on CD14++CD16+ (min-max) |
37.50 (33.46–48.89) |
42.15 (35.45–50.58) |
55.39 (45.14–74.41) |
0.0005 |
|
BR1 level on CD14++CD16− (min-max) |
19.80 (17.58–24.32) |
21.83 (19.84–25.77) |
30.63 (25.72–51.98) |
0.00012 |
|
BR2 level on HLA-DR+CD14+ (min-max) |
64.29 (57.56–79.66) |
76.58 (65.26–85.17) |
80.04 (67.91–87.94) |
0.0189 |
|
BR2 level on CD14++CD16+ (min-max) |
71.58 (61.56–82.08) |
77.61 (55.44–90.31) |
82.90 (72.75–86.99) |
Non sign |
|
BR2 level on CD14++CD16− (min–max) |
68.96 (63.52–82.51) |
80.55 (67.51–90.71) |
85.49 (76.47–89.06) |
0.0144 |